Dr Viive Howell

Laboratory Research Director
Medicine, Northern Clinical School
Kolling Institute of Medical Research

Telephone +61 2 9926 4758
Fax +61 2 9926 4035

Website Bill Walsh Translational Cancer Research Laboratory
Kolling Institute of Medical Research

Map

Research interests

Dr Howell’s area of interest is the genetics and molecular mechanisms of disease. Her primary focus is ovarian epithelial cancer with goals of improving understanding of the causes and progression of this disease and identification of new biomarkers which may facilitate earlier diagnosis. She is developing novel genetic mouse models of ovarian cancer in which to study the complex interplay of hormonal, genetic and other factors that leads to this disease. In addition, she is undertaking in vitro studies to search for novel regulators of signalling pathways that are implicated in ovarian cancer development.

Selected grants

2013

  • Serum microRNAs as predictive tools for optimal cytoreduction in women with serous epithelial ovarian cancer; Marsh D, Howell V, Gard G; Ovarian Cancer Research Foundation/Research Support.
  • A high-throughput, bright-field and fluorescence digital slide scanning platform and service that is both research and teaching-focused and available University-wide.; King N, Graeber M, Naylor M, Slapeta J, Quinnell R, Charles (nee Slaviero) K, Owens T, Bourne R, Braet F, Hambly B, Overall R, Stone J, Twigg S, Hardikar A, Halliday G, Richardson D, Byrne M, Keay K, Marsh D, Howell V, Pollock C, Chen X; DVC Research/Equipment Grant.
  • Towards Personalizing Chemotherapeutic Treatment for Cancer - Investigating Inter-Ethnic Differences in Genetic Susceptibility to Anti-Cancer Drug Toxicity; Howell V, Clarke S; Rebecca L Cooper Medical Research Foundation/Equipment Grant.

2012

  • A random mutagenesis strategy for the identification of new targets for the treatment of malignant melanoma; Howell V; Cure Cancer Australia Foundation/Research Support.
  • Scanning for Mutations in Cancer Susceptibility Genes; Howell V, Kurdyukov S, Bullock M; Rebecca L Cooper Medical Research Foundation/Equipment Grant.

2011

  • IncuCyte FLR Microscope System and Cell Incubator; Baxter R, Marsh D, Jackson C, O'Neill C, Ashton A, Howell V; Clive & Vera Ramaciotti Foundation/Awards for Biomedical Research: Major Equipment.
  • FSH control of ovarian function; Allan C, Handelsman D, Walters K, Howell V; National Health and Medical Research Council (NHMRC)/Project Grants.
  • IncuCyte FLR Microscope System (Essen Bioscience); Marsh D, Baxter R, Morris J, Jackson C, Howell V; National Health and Medical Research Council (NHMRC)/Equipment Grants.
  • New opportunities for the study of ovarian cancer through characterisation of mouse models; Howell V, Gill A; Cancer Council New South Wales/Research Project Grants.

2010

  • In-Vivo Multispectral Imaging FX System: small animal imaging for multi-modal molecular signal localisation in live animals; Marsh D, Baxter R, Ashton A, Howell V, Soon P, Little D, Robinson B; Cancer Institute New South Wales/Equipment Grant.
  • Robotic liquid handling workstation for automated sample preparation - Building capacity in the Kolling Genomics Core Facility; Marsh D, Howell V; Royal North Shore Hospital/Staff Specialist Trust Fund.
  • Identification of novel genes that regulate tumour angiogenesis; Howell V; Royal North Shore Hospital/Area Research Grants.
  • Building capacity in the Kolling Genomics Core Facility - robotic liquid handling workstation for automated sample preparation; Howell V; Northern Sydney Area Health Service/Research Grants Scheme.

2009

  • Ovarian Cancer: Experimental models for understanding the molecular events important to this malignancy; Howell V; Cancer Institute New South Wales/Early Career Development Fellowship.
  • Relationships between miRNA and the phosphatidylinositol 3-kinase/mammamlian target of rapamycin pathway in ovarian cancer; Marsh D, Howell V; DVC Research/Cancer Research Fund.
  • Infrastructure support for the Kolling Institute Genomics Core and Confocal Microscopy Facility; Marsh D, Keast ?, Ashton A, Howell V; Northern Clinical School/Bridging Support Fellowship.

2008

  • A forward genetic approach to identify primary tumorigenic events in mouse ovarian tumours with and without loss of Brcal; Howell V; Northern Sydney and Central Coast Area Health Service/Research Support.
  • Ovarian Surface Epithelial Carcinoma Modelling in Brac1-null mice mediated by Sleeping Beauty insert; Howell V, Marsh D; Cure Cancer Australia Foundation/Research Support.

2005

  • Functional Characterisation Of The Recently Discovered Mammalian Genes, Scnm1 & Hrpt2; Howell V; National Health and Medical Research Council (NHMRC)/Early Career Fellowships (ECF).

Selected publications

Download citations: PDF RTF Endnote

Book Chapters

  • Howell, V., Colvin, E. (2014). Genetically Engineered Insertional Mutagenesis in Mice to Model Cancer: Sleeping Beauty. In Shree Ram Singh and Vincenzo Coppola (Eds.), Mouse Genetics: Methods and Protocols, (pp. 367-383). New York: Springer.
  • Marsh, D., Howell, V. (2010). The Use of Denaturing High Performance Liquid Chromatography (DHPLC) for Mutation Scanning of Hereditary Cancer Genes. In Michelle Webb (Eds.), Cancer Susceptibility: Methods and Protocols, (pp. 133-145). United States: Humana Press.

Journals

  • Fuller, E., Howell, V. (2014). Culture Models to Define Key Mediators of Cancer Matrix Remodeling. Frontiers in Oncology, 4, 1-7. [More Information]
  • Hudson, A., Weir, C., Moon, E., Harvie, R., Klebe, S., Clarke, S., Pavlakis, N., Howell, V. (2014). Establishing a panel of chemo-resistant mesothelioma models for investigating chemo-resistance and identifying new treatments for mesothelioma. Scientific Reports, 4, 6152. [More Information]
  • Hayes, S., Hudson, A., Clarke, S., Molloy, M., Howell, V. (2014). From mice to men: GEMMs as trial patients for new NSCLC therapies. Seminars in Cell & Developmental Biology, 27, 118-127. [More Information]
  • Howell, V. (2014). Genetically engineered mouse models for epithelial ovarian cancer: Are we there yet? Seminars in Cell & Developmental Biology, 27, 106-117. [More Information]
  • Howell, V. (2014). Mice and men working together for over 100 years in the fight against cance. Seminars in Cell and Developmental Biology, 27, 52-53. [More Information]
  • Weir, C., Hudson, A., Moon, E., Ross, A., Alexander, M., Peters, L., Langova, V., Clarke, S., Pavlakis, N., Davey, R., Howell, V. (2014). Streptavidin: a novel immunostimulant for the selection and delivery of autologous and syngeneic tumor vaccines. Cancer Immunology Research, 2(5), 469-479. [More Information]
  • Holt, D., Henthorn, P., Howell, V., Robinson, B., Benn, D. (2014). Succinate Dehydrogenase Subunit D and A Succinate Dehydrogenase Subunit B Mutation Analysis in Canine Phaeochromocytoma and Paraganglioma. Journal of Comparative Pathology, 151(1), 25-34. [More Information]
  • Parker, N., Correia, N., Crossley, B., Buckland, M., Howell, V., Wheeler, H. (2013). Correlation of MicroRNA 132 Up-regulation with an Unfavorable Clinical Outcome in Patients with Primary Glioblastoma Multiforme Treated with Radiotherapy Plus Concomitant and Adjuvant Temozolomide Chemotherapy. Translational Oncology, 6(6), 742-748. [More Information]
  • Hasovits, C., Pavlakis, N., Howell, V., Gill, A., Clarke, S. (2013). Resistance to EGFR targeted antibodies - expansion of clones present from the start of treatment. The more things change, the more they stay the same (Plus ca change, plus ca ne change pas!). Translational Gastrointestinal Cancer, 28(1), 44-46. [More Information]
  • Tang, J., Carmichael, C., Shi, W., Metcalf, D., Ng, A., Hyland, C., Jenkins, N., Copeland, N., Howell, V., Zhao, Z., et al (2013). Transposon mutagenesis reveals cooperation of ETS family transcription factors with signaling pathways in erythro-megakaryocytic leukemia. Proceedings of the National Academy of Sciences (PNAS) of the United States of America, 110(15), 6091-6096. [More Information]
  • Kan, C., Hahn, M., Gard, G., Maidens, J., Huh, J., Marsh, D., Howell, V. (2012). Elevated levels of circulating microRNA-200 family members correlate with serous epithelial ovarian cancer. BMC Cancer, 12, 1-9. [More Information]
  • Le, T., Mardini, M., Howell, V., Funder, J., Ashton, A., Mihailidou, A. (2012). Low-dose spironolactone prevents apoptosis repressor with caspase recruitment domain degradation during myocardial infarction. Hypertension, 59(6), 1164-1169. [More Information]
  • Howell, V. (2012). Sleeping Beauty - a mouse model for all cancers? Cancer Letters, 317(1), 1-8. [More Information]
  • Hahn, M., Howell, V., Gill, A., Clarkson, A., Weaire-Buchanan, G., Robinson, B., Delbridge, L., Gimm, O., Schmitt, W., Teh, B., Marsh, D. (2010). CDC73/HRPT2 CpG island hypermethylation and mutation of 5'-untranslated sequence are uncommon mechanisms of silencing parafibromin in parathyroid tumors. Endocrine-Related Cancer, 17(1), 273-282. [More Information]
  • Howell, V., Gill, A., Clarkson, A., Nelson, A., Dunne, R., Delbridge, L., Robinson, B., Teh, B., Gimm, O., Marsh, D. (2009). Accuracy of Combined Protein Gene Product 9.5 and Parafibromin Markers for Immunohistochemical Diagnosis of Parathyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 94(2), 434-441. [More Information]
  • Howell, V., de Haan, G., Bergren, S., Jones, J., Culiat, C., Michaud, E., Frankel, W., Meisler, M. (2008). A targeted deleterious allele of the splicing factor SCNM1 in the mouse. Genetics, 180(3), 1419-1427. [More Information]
  • Howell, V., Jones, J., Bergren, S., Li, L., Billi, A., Avenarius, M., Meisler, M. (2007). Evidence for a direct role of the disease modifier SCNM1 in splicing. Human Molecular Genetics, 16(20), 2506-2516. [More Information]
  • Marsh, D., Hahn, M., Howell, V., Gill, A. (2007). Molecular diagnosis of primary hyperparathyroidism in familial cancer syndromes. Expert Opinion on Medical Diagnostics, 1(3), 377-392.
  • Gill, A., Clarkson, A., Gimm, O., Keil, J., Dralle, H., Howell, V., Marsh, D. (2006). Loss of Nuclear Expression of Parafibromin Distinguishes Parathyroid Carcinomas and Hyperparathyroidism-Jaw Tumor (HPT-JT) Syndrome-related Adenomas From Sporadic Parathyroid Adenomas and Hyperplasias. American Journal of Surgical Pathology, 30(9), 1140-1149. [More Information]
  • Gimm, O., Lorenz, K., Nguyen Thanh, P., Schneyer, U., Bloching, M., Howell, V., Marsh, D., Teh, B., Krause, U., Dralle, H. (2006). Prophylactic parathyroidectomy for familial parathyroid carcinoma. Chirurg, 77(1), 15-24. [More Information]
  • Howell, V., Cardinal, J., Richardson, A., Gimm, O., Robinson, B., Marsh, D. (2006). Rapid Mutation Screening for HRPT2 and MEN1 Mutations Associated with Familial and Sporadic Primary Hyperparathyroidism. Journal of molecular diagnostics, 8(5), 559-566. [More Information]
  • Howell, V., Zori, R., Stalker, H., Williams, C., Jesse, N., Nelson, A., Robinson, B., Marsh, D. (2004). A molecular diagnosis of hyperparathyroidism-Jaw tumor syndrome in an adolescent with recurrent kidney stones. The Journal of Pediatrics, 145(4), 567-567.
  • Howell, V., Proos, A., La Rue, D., Jensen, C., Beach, F., Burnett, L. (2004). Carrier Screening For Canavan Disease In Australia. Journal of Inherited Metabolic Disease (JIMD), 27(2), 289-290.
  • Haven, C., Howell, V., Eilers, P., Dunne, R., Takahashi, M., Van Puijenbroek, M., Furge, K., Kievit, J., Tan, M., Fleuren, G., Robinson, B., Delbridge, L., Philips, J., Nelson, A., Marsh, D., et al (2004). Gene Expression Of Parathyroid Tumors: Molecular Subclassification And Identification Of The Potential Malignant Phenotype. Cancer Research, 64(20), 7405-7411.
  • Teh, B., Howell, V., Haven, C., Kahnoski, K., Khoo, S., Petillo, D., Chen, J., Fleuren, G., Robinson, B., Delbridge, L., et al (2004). Human Gene Mutations - Gene Symbol: HRPT2. Disease: Hyperparathyroidism Jaw-tumor syndrome. Human Genetics, 114(2), 221-224.
  • Barlow-Stewart, K., Burnett, L., Proos, A., Howell, V., Huq, F., Lazarus, R., Aizenberg, H. (2003). A genetic screening programme for Tay-Sachs disease and cystic fibrosis for Australian Jewish high School students. Journal of Medical Genetics, 40(e45), 1-8.
  • Howell, V., Haven, C., Kahnoski, K., Khoo, S., Petillo, D., Chen, J., Fleuren, G., Robinson, B., Delbridge, L., Philips, J., Marsh, D., et al (2003). HRPT2 mutations are associated with malignancy in sporadic parathyroid tumours. Journal of Medical Genetics, 40(9), 657-663.
  • Marsh, D., Howell, V., Benn, D., Robinson, B., Theodosopoulos, G., Riches, J., Proos, A., Eng,, C. (2001). Rapid mutation scanning of genes associated with familial cancer syndromes using denaturing high-performance liquid chromatography. Neoplasia (Spanish Edition): oncologia multidisciplinaria, 3, 236-244.

2014

  • Fuller, E., Howell, V. (2014). Culture Models to Define Key Mediators of Cancer Matrix Remodeling. Frontiers in Oncology, 4, 1-7. [More Information]
  • Hudson, A., Weir, C., Moon, E., Harvie, R., Klebe, S., Clarke, S., Pavlakis, N., Howell, V. (2014). Establishing a panel of chemo-resistant mesothelioma models for investigating chemo-resistance and identifying new treatments for mesothelioma. Scientific Reports, 4, 6152. [More Information]
  • Hayes, S., Hudson, A., Clarke, S., Molloy, M., Howell, V. (2014). From mice to men: GEMMs as trial patients for new NSCLC therapies. Seminars in Cell & Developmental Biology, 27, 118-127. [More Information]
  • Howell, V., Colvin, E. (2014). Genetically Engineered Insertional Mutagenesis in Mice to Model Cancer: Sleeping Beauty. In Shree Ram Singh and Vincenzo Coppola (Eds.), Mouse Genetics: Methods and Protocols, (pp. 367-383). New York: Springer.
  • Howell, V. (2014). Genetically engineered mouse models for epithelial ovarian cancer: Are we there yet? Seminars in Cell & Developmental Biology, 27, 106-117. [More Information]
  • Howell, V. (2014). Mice and men working together for over 100 years in the fight against cance. Seminars in Cell and Developmental Biology, 27, 52-53. [More Information]
  • Weir, C., Hudson, A., Moon, E., Ross, A., Alexander, M., Peters, L., Langova, V., Clarke, S., Pavlakis, N., Davey, R., Howell, V. (2014). Streptavidin: a novel immunostimulant for the selection and delivery of autologous and syngeneic tumor vaccines. Cancer Immunology Research, 2(5), 469-479. [More Information]
  • Holt, D., Henthorn, P., Howell, V., Robinson, B., Benn, D. (2014). Succinate Dehydrogenase Subunit D and A Succinate Dehydrogenase Subunit B Mutation Analysis in Canine Phaeochromocytoma and Paraganglioma. Journal of Comparative Pathology, 151(1), 25-34. [More Information]

2013

  • Parker, N., Correia, N., Crossley, B., Buckland, M., Howell, V., Wheeler, H. (2013). Correlation of MicroRNA 132 Up-regulation with an Unfavorable Clinical Outcome in Patients with Primary Glioblastoma Multiforme Treated with Radiotherapy Plus Concomitant and Adjuvant Temozolomide Chemotherapy. Translational Oncology, 6(6), 742-748. [More Information]
  • Hasovits, C., Pavlakis, N., Howell, V., Gill, A., Clarke, S. (2013). Resistance to EGFR targeted antibodies - expansion of clones present from the start of treatment. The more things change, the more they stay the same (Plus ca change, plus ca ne change pas!). Translational Gastrointestinal Cancer, 28(1), 44-46. [More Information]
  • Tang, J., Carmichael, C., Shi, W., Metcalf, D., Ng, A., Hyland, C., Jenkins, N., Copeland, N., Howell, V., Zhao, Z., et al (2013). Transposon mutagenesis reveals cooperation of ETS family transcription factors with signaling pathways in erythro-megakaryocytic leukemia. Proceedings of the National Academy of Sciences (PNAS) of the United States of America, 110(15), 6091-6096. [More Information]

2012

  • Kan, C., Hahn, M., Gard, G., Maidens, J., Huh, J., Marsh, D., Howell, V. (2012). Elevated levels of circulating microRNA-200 family members correlate with serous epithelial ovarian cancer. BMC Cancer, 12, 1-9. [More Information]
  • Le, T., Mardini, M., Howell, V., Funder, J., Ashton, A., Mihailidou, A. (2012). Low-dose spironolactone prevents apoptosis repressor with caspase recruitment domain degradation during myocardial infarction. Hypertension, 59(6), 1164-1169. [More Information]
  • Howell, V. (2012). Sleeping Beauty - a mouse model for all cancers? Cancer Letters, 317(1), 1-8. [More Information]

2010

  • Hahn, M., Howell, V., Gill, A., Clarkson, A., Weaire-Buchanan, G., Robinson, B., Delbridge, L., Gimm, O., Schmitt, W., Teh, B., Marsh, D. (2010). CDC73/HRPT2 CpG island hypermethylation and mutation of 5'-untranslated sequence are uncommon mechanisms of silencing parafibromin in parathyroid tumors. Endocrine-Related Cancer, 17(1), 273-282. [More Information]
  • Marsh, D., Howell, V. (2010). The Use of Denaturing High Performance Liquid Chromatography (DHPLC) for Mutation Scanning of Hereditary Cancer Genes. In Michelle Webb (Eds.), Cancer Susceptibility: Methods and Protocols, (pp. 133-145). United States: Humana Press.

2009

  • Howell, V., Gill, A., Clarkson, A., Nelson, A., Dunne, R., Delbridge, L., Robinson, B., Teh, B., Gimm, O., Marsh, D. (2009). Accuracy of Combined Protein Gene Product 9.5 and Parafibromin Markers for Immunohistochemical Diagnosis of Parathyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 94(2), 434-441. [More Information]

2008

  • Howell, V., de Haan, G., Bergren, S., Jones, J., Culiat, C., Michaud, E., Frankel, W., Meisler, M. (2008). A targeted deleterious allele of the splicing factor SCNM1 in the mouse. Genetics, 180(3), 1419-1427. [More Information]

2007

  • Howell, V., Jones, J., Bergren, S., Li, L., Billi, A., Avenarius, M., Meisler, M. (2007). Evidence for a direct role of the disease modifier SCNM1 in splicing. Human Molecular Genetics, 16(20), 2506-2516. [More Information]
  • Marsh, D., Hahn, M., Howell, V., Gill, A. (2007). Molecular diagnosis of primary hyperparathyroidism in familial cancer syndromes. Expert Opinion on Medical Diagnostics, 1(3), 377-392.

2006

  • Gill, A., Clarkson, A., Gimm, O., Keil, J., Dralle, H., Howell, V., Marsh, D. (2006). Loss of Nuclear Expression of Parafibromin Distinguishes Parathyroid Carcinomas and Hyperparathyroidism-Jaw Tumor (HPT-JT) Syndrome-related Adenomas From Sporadic Parathyroid Adenomas and Hyperplasias. American Journal of Surgical Pathology, 30(9), 1140-1149. [More Information]
  • Gimm, O., Lorenz, K., Nguyen Thanh, P., Schneyer, U., Bloching, M., Howell, V., Marsh, D., Teh, B., Krause, U., Dralle, H. (2006). Prophylactic parathyroidectomy for familial parathyroid carcinoma. Chirurg, 77(1), 15-24. [More Information]
  • Howell, V., Cardinal, J., Richardson, A., Gimm, O., Robinson, B., Marsh, D. (2006). Rapid Mutation Screening for HRPT2 and MEN1 Mutations Associated with Familial and Sporadic Primary Hyperparathyroidism. Journal of molecular diagnostics, 8(5), 559-566. [More Information]

2004

  • Howell, V., Zori, R., Stalker, H., Williams, C., Jesse, N., Nelson, A., Robinson, B., Marsh, D. (2004). A molecular diagnosis of hyperparathyroidism-Jaw tumor syndrome in an adolescent with recurrent kidney stones. The Journal of Pediatrics, 145(4), 567-567.
  • Howell, V., Proos, A., La Rue, D., Jensen, C., Beach, F., Burnett, L. (2004). Carrier Screening For Canavan Disease In Australia. Journal of Inherited Metabolic Disease (JIMD), 27(2), 289-290.
  • Haven, C., Howell, V., Eilers, P., Dunne, R., Takahashi, M., Van Puijenbroek, M., Furge, K., Kievit, J., Tan, M., Fleuren, G., Robinson, B., Delbridge, L., Philips, J., Nelson, A., Marsh, D., et al (2004). Gene Expression Of Parathyroid Tumors: Molecular Subclassification And Identification Of The Potential Malignant Phenotype. Cancer Research, 64(20), 7405-7411.
  • Teh, B., Howell, V., Haven, C., Kahnoski, K., Khoo, S., Petillo, D., Chen, J., Fleuren, G., Robinson, B., Delbridge, L., et al (2004). Human Gene Mutations - Gene Symbol: HRPT2. Disease: Hyperparathyroidism Jaw-tumor syndrome. Human Genetics, 114(2), 221-224.

2003

  • Barlow-Stewart, K., Burnett, L., Proos, A., Howell, V., Huq, F., Lazarus, R., Aizenberg, H. (2003). A genetic screening programme for Tay-Sachs disease and cystic fibrosis for Australian Jewish high School students. Journal of Medical Genetics, 40(e45), 1-8.
  • Howell, V., Haven, C., Kahnoski, K., Khoo, S., Petillo, D., Chen, J., Fleuren, G., Robinson, B., Delbridge, L., Philips, J., Marsh, D., et al (2003). HRPT2 mutations are associated with malignancy in sporadic parathyroid tumours. Journal of Medical Genetics, 40(9), 657-663.

2001

  • Marsh, D., Howell, V., Benn, D., Robinson, B., Theodosopoulos, G., Riches, J., Proos, A., Eng,, C. (2001). Rapid mutation scanning of genes associated with familial cancer syndromes using denaturing high-performance liquid chromatography. Neoplasia (Spanish Edition): oncologia multidisciplinaria, 3, 236-244.

To update your profile click here. For support on your academic profile contact .